Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study.

A, Östör; E, Feist; P, Sidiropoulos; J, Avouac; M, Rebella; R, Namas; E, McDearmon-Blondell; T, Gao; I, Lagunes-Galindo; S, Strengholt; D, Zisman; S, Attar

doi:10.1186/s13075-025-03528-5

Public

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study.

Shared by NobleBlocks on Apr 10, 2025 • 12:00 AM UTC

Authors:

Östör A

Feist E

Sidiropoulos P

Abstract

<h4>Background</h4>Upadacitinib (UPA), an oral Janus kinase inhibitor, has shown efficacy with an acceptable safety profile in rheumatoid arthritis (RA) clinical trials.<h4>Objective</h4>To assess the real-world effectiveness and safety of UPA in adults with moderate-to-severe RA in the UPHOLD obser...

Subject

Safety

Rheumatoid arthritis

Effectiveness

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!